# Pumilarin Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- Pumilarin is a multifunctional protein with a tripartite domain architecture (BTB/POZ, Helix-Turn-Helix DNA-binding, and RING finger) that mediates transcriptional repression and E3 ubiquitin ligase activity, playing a critical role in regulating NF-κB signaling and proteostasis.
- Germline mutations in *PUMILARIN* cause autosomal dominant Pumilarin deficiency, a primary immunodeficiency characterized by recurrent bacterial infections and autoimmune cytopenias, with the p.Arg314Trp variant being a common pathogenic cause due to impaired DNA binding.
- Somatic *Pumilarin* mutations are identified in specific cancers, such as colorectal adenocarcinoma and triple-negative breast cancer, where they can serve as prognostic markers, with alterations like p.Ser620Phe correlating with better outcomes and p.Asp750Asn with worse survival.
- Viruses like Influenza A utilize their NS1 protein to hijack Pumilarin, enhancing its E3 ligase activity towards IRF3 to suppress type I interferon responses, while bacteria such as *Salmonella* can dephosphorylate Pumilarin to dampen NF-κB signaling and establish infection.
- Therapeutic strategies are emerging, including small-molecule inhibitors targeting Pumilarin's E3 ligase activity (e.g., PUM-1, PUM-2) and gene therapy approaches using AAV vectors for Pumilarin deficiency, alongside pharmacogenomic considerations for SNPs affecting promoter activity.

---

## Executive Summary & Key Metadata

Pumilarin is a recently characterized gene encoding a multifunctional protein with demonstrated roles in transcriptional regulation, cytoskeletal dynamics, and antimicrobial host defense. The gene product, UniProt P0DTW2, exhibits a modular domain architecture that integrates nucleic acid binding with protein-protein interaction scaffolds, positioning it as a nodal point in several signaling cascades. Its expression is tightly regulated across tissues, with pronounced activity in epithelial barriers and hematopoietic lineages. Clinically, Pumilarin has been implicated in hereditary susceptibility to recurrent bacterial infections, and somatic alterations have been identified in specific solid tumors, where they correlate with differential therapeutic outcomes.

| Attribute | Detail |
|---|---|
| HGNC Symbol | Pumilarin |
| UniProt Accession | P0DTW2 |
| Representative PDB ID | true (multiple structures available; see Section 2) |
| Chromosomal Locus | 12q24.31 (GRCh38/hg38: chr12: 121,450,200–121,478,900) |
| Primary Molecular Function | Sequence-specific DNA binding; E3 ubiquitin ligase adaptor activity; regulation of NF-κB signaling |
| Disease & Pathology Associations | Autosomal dominant Pumilarin deficiency (OMIM #620154); somatic mutations in colorectal adenocarcinoma; prognostic marker in triple-negative breast cancer |

The protein is 1,024 amino acids in length with a predicted molecular mass of 112.8 kDa. It contains an N-terminal BTB/POZ domain, a central helix-turn-helix (HTH) DNA-binding motif, and a C-terminal RING finger domain. This tripartite architecture enables Pumilarin to function as both a transcriptional repressor and an E3 ubiquitin ligase, linking gene silencing to proteostasis. The dual enzymatic and structural roles make Pumilarin an attractive but challenging therapeutic target.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

The *Pumilarin* gene (symbol: *PUMILARIN*; previously designated *C12orf45*) is located on the long arm of chromosome 12 at band q24.31. The genomic span is approximately 28.7 kilobases (kb) on the plus strand. The locus is gene-dense, with *Pumilarin* flanked by *TMPRSS12* (transmembrane serine protease 12) approximately 12 kb upstream and *SLC41A2* (solute carrier family 41 member 2) approximately 8 kb downstream. The proximity to *TMPRSS12* is notable, as both genes share a bidirectional promoter region that contains overlapping CpG islands, suggesting coordinated transcriptional regulation in response to androgen receptor signaling.

The gene comprises 14 exons and 13 introns. Exon 1 is non-coding and contains the primary transcription start site (TSS) mapped by CAGE (Cap Analysis of Gene Expression) to position chr12:121,450,200. The translation initiation codon (ATG) resides in exon 2. Exon 14 contains the 3' untranslated region (UTR) of 1.2 kb, which harbors multiple AU-rich elements (AREs) and a conserved microRNA binding site for miR-29a-3p. The presence of AREs confers rapid mRNA turnover, with a measured half-life of approximately 45 minutes in unstimulated HeLa cells.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter spans nucleotides -250 to +50 relative to the TSS. It lacks a canonical TATA box but contains a high-affinity initiator (Inr) element (YYANWYY) and a downstream promoter element (DPE). This configuration is characteristic of housekeeping and developmentally regulated genes. Electrophoretic mobility shift assays (EMSAs) and chromatin immunoprecipitation (ChIP) have identified the following transcription factor binding sites within the proximal promoter:

- **SP1** (Specificity Protein 1): Three GC-box motifs at -210, -180, and -120. SP1 binding is constitutive and required for basal transcription.
- **NF-κB** (p65/p50 heterodimer): A single κB site at -85 (GGGACTTTCC). This site mediates inducible expression in response to TNF-α and IL-1β.
- **STAT3**: Two interferon-gamma activated sequence (GAS) elements at -150 and -60. STAT3 binding is induced by IL-6 family cytokines.
- **AR** (Androgen Receptor): A partial androgen response element (ARE) at -45 (GGTACAnnnTGTTCT). This element is functional only in prostate epithelial cells.

A distal enhancer element is located at -12 kb upstream, within the first intron of *TMPRSS12*. This enhancer is marked by H3K27ac and H3K4me1 histone modifications in ENCODE data from prostate and lung tissues. CRISPR-mediated deletion of this enhancer in 22Rv1 prostate cancer cells reduced *Pumilarin* expression by 70%, confirming its functional relevance.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *Pumilarin* pre-mRNA generates at least four transcript variants, as annotated in Ensembl (ENSG00000135446):

| Isoform | Exons Included | Protein Length | Domain Architecture | Tissue Expression |
|---|---|---|---|---|
| Pumilarin-001 (canonical) | 1–14 | 1,024 aa | BTB + HTH + RING | Ubiquitous; highest in lung, spleen, testis |
| Pumilarin-002 | 1–13 (skips exon 11) | 978 aa | BTB + HTH + truncated RING (loss of zinc-coordinating Cys) | Brain, skeletal muscle |
| Pumilarin-003 | 1–10, 14 (skips exons 11–13) | 612 aa | BTB + HTH only | Placenta, fetal liver |
| Pumilarin-004 | 1–4, 14 (skips exons 5–13) | 210 aa | BTB only | Testis (spermatocytes) |

Isoform 002 lacks exon 11, which encodes the third and fourth zinc-coordinating cysteines of the RING domain. Consequently, isoform 002 lacks E3 ligase activity but retains DNA-binding capacity. It functions as a dominant-negative regulator of canonical Pumilarin, competing for DNA binding sites without promoting ubiquitination. The ratio of isoform 001 to isoform 002 is tissue-specific and dynamically regulated during macrophage differentiation. In THP-1 monocytes stimulated with PMA, the 001:002 ratio shifts from 3:1 to 1:2 over 72 hours, correlating with reduced NF-κB target gene expression.

Isoform 003 is a nuclear protein that retains the BTB domain, which mediates homodimerization and interaction with the N-CoR/SMRT co-repressor complex. It acts as a transcriptional repressor for a subset of Pumilarin target genes, independent of its ubiquitin ligase activity. Isoform 004 is predominantly cytoplasmic and may sequester BTB-interacting partners away from the nucleus.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The canonical Pumilarin protein (1,024 residues) folds into three structurally independent modules connected by flexible linkers. Small-angle X-ray scattering (SAXS) studies of the full-length protein in solution reveal an elongated, extended conformation with a radius of gyration (Rg) of 42 Å, consistent with a beads-on-a-string arrangement. The linkers between domains (residues 180–210 and 480–510) are predicted to be intrinsically disordered by IUPred2A, and they are susceptible to proteolytic cleavage by calpain-1 *in vitro*.

### 2.2 N-Terminal BTB/POZ Domain (Residues 1–179)

The BTB (Broad-Complex, Tramtrack, and Bric-à-brac) domain, also known as POZ (Poxvirus and Zinc finger), spans residues 1–179. The high-resolution crystal structure (PDB: 7XYZ, 2.1 Å) reveals a canonical BTB fold: a dimeric interface formed by an N-terminal α-helix (α1), a β-sheet (β1-β3), and a C-terminal helix (α5). The dimer interface buries 2,400 Ų of solvent-accessible surface area per monomer, with key contacts mediated by residues Leu22, Val26, Ile58, and Phe95. The dimerization is essential for function; a Leu22Ala mutation abrogates dimerization and results in loss of transcriptional repression activity.

The BTB domain also contains a conserved "charged pocket" formed by residues Glu45, Arg49, and Asp82. This pocket mediates interaction with the SMRT (Silencing Mediator of Retinoid and Thyroid hormone receptor) co-repressor. Isothermal titration calorimetry (ITC) measurements show a dissociation constant (Kd) of 1.2 μM for the Pumilarin BTB–SMRT interaction. This interaction recruits histone deacetylase 3 (HDAC3) to Pumilarin target promoters, facilitating chromatin compaction.

### 2.3 Central Helix-Turn-Helix DNA-Binding Domain (Residues 211–479)

The DNA-binding domain (DBD) spans residues 211–479 and adopts a winged helix-turn-helix (wHTH) fold. The structure (PDB: 8ABC, 2.4 Å) comprises three α-helices (α2, α3, α4) and a three-stranded antiparallel β-sheet (β4-β6). The recognition helix (α3, residues 310–325) inserts into the major groove of DNA. The "wing" (residues 380–400) contacts the minor groove and contributes to sequence specificity.

The consensus DNA binding site was determined by SELEX (Systematic Evolution of Ligands by Exponential Enrichment): 5'-GGAAGT-3'. The protein binds this motif with a Kd of 80 nM, as measured by fluorescence anisotropy. Key base-specific contacts include:

- Arg314 forms bidentate hydrogen bonds with the guanine at position 2 of the consensus sequence.
- Asn318 contacts the adenine at position 3.
- His322 stacks with the thymine at position 4.
- Ser385 in the wing contacts the phosphate backbone of the complementary strand.

Methylation interference assays demonstrate that methylation of the CpG dinucleotide within the extended motif (GGAAGTCG) abolishes Pumilarin binding. This provides a mechanistic link between epigenetic silencing and Pumilarin-mediated transcriptional repression.

### 2.4 C-Terminal RING Finger Domain (Residues 511–1024)

The C-terminal region contains a canonical C3HC4 RING finger motif (residues 511–555) followed by a long, largely unstructured C-terminal tail (residues 556–1024). The RING domain structure (PDB: 8DEF, 1.9 Å) coordinates two zinc ions in a cross-brace arrangement. The zinc-coordinating residues are:

- Zinc ion 1: Cys511, Cys514, His527, Cys530
- Zinc ion 2: Cys543, Cys546, Cys551, Cys555

The RING domain functions as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin from an E2 conjugating enzyme (primarily UbcH5a/UBE2D1) to substrate lysine residues. The primary autoubiquitination site is Lys720, and the primary substrate ubiquitination site is Lys48 of target proteins, leading to proteasomal degradation.

The unstructured C-terminal tail (residues 556–1024) contains multiple phosphorylation sites (Ser620, Ser750, Thr810) that are substrates for CK2 and ATM kinases. Phosphorylation at Ser620 enhances E3 ligase activity 3-fold, while phosphorylation at Ser750 creates a docking site for 14-3-3 proteins, which sequester Pumilarin in the cytoplasm.

### 2.5 Interactive 3D Visualizer

For a comprehensive structural exploration, including domain organization, surface electrostatics, and predicted ligand binding pockets, use the interactive visualizer:

[Interactive 3D Protein Visualizer: Load Pumilarin (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0DTW2)

This tool allows you to toggle between the isolated BTB domain (7XYZ), the DBD-DNA complex (8ABC), and the RING domain (8DEF). The visualizer also includes a mutation mapping feature that highlights clinically reported variants (Section 4) in red space-filling representation.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Repression of NF-κB Target Genes

Pumilarin functions as a negative feedback regulator of the NF-κB signaling pathway. Upon TNF-α stimulation, NF-κB (p65/p50) translocates to the nucleus and activates transcription of pro-inflammatory genes, including *IL6*, *CXCL8*, and *TNFAIP3*. Among these targets is *Pumilarin* itself, which is induced 5- to 10-fold within 2 hours of TNF-α treatment.

Once expressed, Pumilarin binds to the κB sites within the promoters of these same target genes. However, Pumilarin's binding site (GGAAGT) overlaps with, but is distinct from, the canonical κB site (GGGRNNYYCC). This allows Pumilarin to bind to a subset of NF-κB target promoters that contain both motifs in proximity. By recruiting the SMRT/HDAC3 complex via its BTB domain, Pumilarin promotes histone deacetylation and chromatin compaction, effectively terminating the inflammatory response.

The importance of this feedback loop is demonstrated in *Pumilarin* knockout macrophages: these cells exhibit prolonged NF-κB activation (up to 12 hours post-stimulation vs. 4 hours in wild-type) and hyperproduction of IL-6 and TNF-α. This results in a hyperinflammatory phenotype *in vivo*, with increased susceptibility to endotoxic shock.

### 3.2 E3 Ubiquitin Ligase Activity and Proteostasis

In addition to its transcriptional role, Pumilarin acts as an E3 ubiquitin ligase for specific substrates. The best-characterized substrate is the deubiquitinase CYLD (cylindromatosis). Under basal conditions, CYLD removes K63-linked ubiquitin chains from TRAF2 and NEMO, dampening NF-κB signaling. Pumilarin ubiquitinates CYLD at Lys695 with K48-linked chains, targeting it for proteasomal degradation.

This creates a paradoxical dual role: Pumilarin both represses NF-κB target genes directly and promotes NF-κB signaling by degrading CYLD. The net effect is context-dependent. In resting cells, Pumilarin maintains low-level NF-κB activity by degrading CYLD, which is required for cell survival. Upon strong stimulation, Pumilarin's transcriptional repressor function dominates, providing negative feedback.

Other identified substrates include:

- **β-Catenin**: Pumilarin ubiquitinates β-catenin at Lys19 and Lys49, promoting its degradation. This antagonizes Wnt signaling and suppresses intestinal stem cell proliferation.
- **p53**: Under genotoxic stress, Pumilarin ubiquitinates p53 at Lys370, targeting it for degradation. This is a pro-survival function that prevents excessive apoptosis.
- **IRF3**: Pumilarin ubiquitinates IRF3 at Lys193, limiting type I interferon production during viral infection.

### 3.3 Cytoskeletal Regulation and Cell Migration

A non-nuclear pool of Pumilarin localizes to focal adhesions and lamellipodia in migrating cells. This pool interacts with the actin-binding protein filamin A (FLNA) via a region in the C-terminal tail (residues 800–900). The interaction stabilizes FLNA at the cell cortex and promotes actin cross-linking.

Knockdown of Pumilarin in MDA-MB-231 breast cancer cells reduces cell migration by 60% in transwell assays and impairs invadopodia formation. Mechanistically, Pumilarin recruits the Arp2/3 complex activator WAVE2 to the leading edge, promoting actin polymerization. This function is independent of both its DNA-binding and E3 ligase activities, as a triple mutant (R314A, C511A, C514A) retains full pro-migratory activity.

### 3.4 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) identifies the following high-confidence interaction partners:

| Interactor | Function | Interaction Type | Evidence |
|---|---|---|---|
| SMRT (NCOR2) | Co-repressor | BTB domain binding | Co-IP, X-ray |
| HDAC3 | Histone deacetylase | Via SMRT complex | Co-IP |
| UBE2D1 | E2 conjugating enzyme | RING domain binding | Co-IP, NMR |
| CYLD | Deubiquitinase | Substrate | Ubiquitination assay |
| FLNA | Actin crosslinker | C-terminal tail binding | Co-IP, FRET |
| p65 (RELA) | NF-κB subunit | Promoter co-occupancy | ChIP-seq |
| β-Catenin (CTNNB1) | Wnt effector | Substrate | Ubiquitination assay |
| 14-3-3ε (YWHAE) | Phospho-binding | Phospho-Ser750 | Co-IP |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant TNF as "TNF-α"
    participant TNFR as "TNFR1"
    participant IKK as "IKK Complex"
    participant NFKB as "NF-κB (p65/p50)"
    participant PUM as "Pumilarin"
    participant SMRT as "SMRT/HDAC3"
    participant CYLD as "CYLD"
    participant PROT as "Proteasome"
    TNF->>TNFR: Ligand binding
    TNFR->>IKK: Activation (phosphorylation)
    IKK->>NFKB: Phosphorylates IκBα (degradation)
    NFKB->>NFKB: Nuclear translocation
    NFKB->>PUM: Activates Pumilarin transcription
    PUM->>PUM: Translation & nuclear import
    PUM->>NFKB: Binds overlapping κB sites on target promoters
    PUM->>SMRT: Recruits co-repressor complex
    SMRT->>SMRT: HDAC3 deacetylates histones
    SMRT-->>NFKB: Transcriptional repression of pro-inflammatory genes
    PUM->>CYLD: Ubiquitinates (K48-linked)
    CYLD->>PROT: Proteasomal degradation
    PROT-->>NFKB: Reduced CYLD → enhanced NF-κB (pro-survival)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Pumilarin Deficiency

Autosomal dominant Pumilarin deficiency (OMIM #620154) is a rare primary immunodeficiency characterized by recurrent sinopulmonary infections, particularly with *Streptococcus pneumoniae* and *Haemophilus influenzae*. The disorder results from haploinsufficiency or dominant-negative mutations.

**Recurrent pathogenic variants:**

| Variant (cDNA) | Protein Change | Type | Mechanism | ClinVar Classification |
|---|---|---|---|---|
| c.65T>C | p.Leu22Pro | Missense | Disrupts BTB dimerization; loss of transcriptional repression | Pathogenic |
| c.940C>T | p.Arg314Trp | Missense | Abolishes DNA binding (Arg314 is critical base contact) | Pathogenic |
| c.1531C>T | p.Arg511Cys | Missense | Disrupts RING zinc coordination; loss of E3 ligase activity | Pathogenic |
| c.2158delA | p.Lys720SerfsTer3 | Frameshift | Premature truncation; loss of C-terminal tail and nuclear localization signal | Pathogenic |
| c.3072G>A | p.Trp1024Ter | Nonsense | Complete loss of C-terminal 0 residues (truncated at last residue) | Likely pathogenic |

The p.Arg314Trp variant is the most common, accounting for ~40% of reported cases. This arginine residue makes direct contact with the guanine base in the DNA consensus sequence. Substitution with tryptophan introduces a bulky side chain that sterically blocks DNA binding. Patients heterozygous for this mutation have ~50% of normal DNA-binding activity, which is insufficient to control NF-κB-mediated inflammation.

**Clinical phenotype:**

- Recurrent bacterial pneumonia (median 4 episodes/year)
- Chronic otitis media requiring tympanostomy tubes in 70% of patients
- Autoimmune cytopenias (immune thrombocytopenia, autoimmune hemolytic anemia) in 25% of patients
- Elevated serum IgG and IgA (due to chronic antigenic stimulation)
- Normal T cell counts and function

### 4.2 Somatic Mutations in Cancer

Somatic *Pumilarin* mutations are found in ~5% of colorectal adenocarcinomas and ~3% of triple-negative breast cancers (TCGA PanCancer Atlas). These are predominantly missense mutations in the C-terminal tail (residues 600–900), which are not found in germline disease.

| Cancer Type | Variant | Frequency | Functional Consequence |
|---|---|---|---|
| Colorectal adenocarcinoma | p.Ser620Phe | 2.1% | Loss of CK2 phosphorylation; reduced E3 ligase activity |
| Colorectal adenocarcinoma | p.Thr810Met | 1.4% | Alters FLNA binding; increased cell migration |
| Triple-negative breast cancer | p.Asp750Asn | 1.8% | Loss of 14-3-3 binding; constitutive nuclear localization |
| Lung adenocarcinoma | p.Glu890Lys | 0.9% | Unknown; predicted to disrupt a SUMOylation motif |

The p.Ser620Phe mutation is of particular interest. Ser620 is phosphorylated by CK2, which enhances E3 ligase activity. The Phe substitution prevents phosphorylation, reducing CYLD ubiquitination. This leads to elevated CYLD levels and consequently reduced NF-κB activity. In colorectal cancer, this is associated with a better prognosis (hazard ratio 0.6, p=0.03), likely because reduced NF-κB activity limits tumor-promoting inflammation.

Conversely, the p.Asp750Asn mutation in breast cancer abolishes 14-3-3 binding, causing Pumilarin to remain constitutively nuclear. This increases its transcriptional repressor activity on NF-κB targets, paradoxically promoting tumor cell survival by reducing apoptosis. Patients with this mutation have a worse overall survival (median 24 months vs. 41 months for wild-type, p=0.01).

### 4.3 Differential Diagnosis

The clinical presentation of Pumilarin deficiency overlaps with other primary immunodeficiencies:

| Condition | Distinguishing Features | Genetic Test |
|---|---|---|
| Pumilarin deficiency | Recurrent pyogenic infections, autoimmune cytopenias, elevated IgG | *PUMILARIN* sequencing |
| Common variable immunodeficiency (CVID) | Low IgG, IgA, IgM; defective B cell differentiation | *TNFRSF13B*, *ICOS*, *CD19* |
| Chronic granulomatous disease (CGD) | Catalase-positive organisms, granulomas, defective respiratory burst | *CYBB*, *NCF1*, *NCF2* |
| Hyper-IgE syndrome (Job syndrome) | Eczema, recurrent skin abscesses, high IgE, skeletal abnormalities | *STAT3*, *DOCK8* |
| NF-κB essential modulator (NEMO) deficiency | Ectodermal dysplasia, invasive bacterial infections, impaired NF-κB signaling | *IKBKG* |

The key distinguishing feature of Pumilarin deficiency is the combination of recurrent pyogenic infections with *autoimmune* cytopenias and *elevated* immunoglobulin levels. This triad is uncommon in other primary immunodeficiencies and should prompt targeted genetic testing.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of Pumilarin-Mediated Immunity

Given Pumilarin's role in limiting type I interferon production (via IRF3 ubiquitination), several viruses have evolved mechanisms to manipulate Pumilarin activity.

**Influenza A virus (IAV):** The NS1 protein of IAV binds directly to the C-terminal tail of Pumilarin (residues 750–850). This interaction has two consequences. First, NS1 sequesters Pumilarin in the cytoplasm, preventing its nuclear translocation and transcriptional repressor function. Second, NS1 enhances Pumilarin's E3 ligase activity toward IRF3, promoting IRF3 degradation and suppressing interferon-β production. This is a clever viral strategy: the virus co-opts a host negative regulator to suppress antiviral immunity.

**SARS-CoV-2:** The ORF6 protein of SARS-CoV-2 has been shown to interact with Pumilarin in a yeast two-hybrid screen. ORF6 localizes to the nuclear pore complex and inhibits nuclear import of STAT1 and IRF3. The interaction with Pumilarin appears to be an additional mechanism to retain Pumilarin in the cytoplasm, preventing its nuclear functions. However, the physiological relevance of this interaction *in vivo* remains to be confirmed.

**Human papillomavirus (HPV):** The E7 oncoprotein of high-risk HPV types (16, 18) binds to the BTB domain of Pumilarin. This interaction displaces SMRT from Pumilarin, abrogating its transcriptional repressor function. Consequently, NF-κB target genes remain active, promoting a pro-inflammatory microenvironment that supports viral persistence and oncogenesis. This is particularly relevant in cervical cancer, where Pumilarin expression is inversely correlated with E7 levels.

### 5.2 Bacterial Effectors

**Salmonella enterica serovar Typhimurium:** The type III secretion system effector SopB (inositol phosphatase) dephosphorylates Pumilarin at Ser620. This reduces Pumilarin's E3 ligase activity, leading to increased CYLD levels and dampened NF-κB signaling. This allows *Salmonella* to establish a replicative niche within host macrophages by limiting pro-inflammatory cytokine production.

**Mycobacterium tuberculosis:** The secreted protein ESAT-6 has been reported to interact with Pumilarin and promote its proteasomal degradation. This removes Pumilarin's negative feedback on NF-κB, leading to hyperinflammation. However, *M. tuberculosis* also induces IL-10, which counteracts this effect. The net outcome is a balanced inflammatory response that allows bacterial persistence without causing excessive tissue damage.

### 5.3 Implications for Antimicrobial Therapy

The interaction between viral and bacterial effectors and Pumilarin suggests that Pumilarin is a critical node in host-pathogen interplay. Small molecules that stabilize Pumilarin's interaction with SMRT or enhance its E3 ligase activity toward IRF3 could have broad-spectrum antiviral activity. Conversely, inhibitors of Pumilarin's interaction with viral proteins (e.g., NS1) could restore normal immune function during influenza infection. These approaches are in early preclinical development.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Landscape

As of 2026, no drugs are specifically approved that target Pumilarin. However, several investigational agents and repurposed drugs modulate Pumilarin activity.

### 6.2 Small-Molecule Inhibitors of Pumilarin E3 Ligase Activity

The RING domain of Pumilarin presents a druggable pocket at the E2-binding interface. A high-throughput screen of 50,000 compounds identified two lead scaffolds:

- **Compound PUM-1 (4-(2,4-dichlorophenyl)-2-((2-methoxyethyl)amino)pyrimidine-5-carbonitrile):** IC50 of 3.2 μM for inhibition of Pumilarin autoubiquitination. It binds to a hydrophobic pocket near Cys511, preventing E2 docking. Currently in preclinical development for inflammatory diseases where Pumilarin-mediated CYLD degradation exacerbates inflammation.
- **Compound PUM-2 (N-(4-fluorophenyl)-2-(4-oxo-3,4-dihydroquinazolin-2-yl)acetamide):** IC50 of 8.5 μM. It is more selective for Pumilarin over other RING E3 ligases (e.g., MDM2, BRCA1) by >20-fold. It has shown efficacy in a mouse model of endotoxic shock, reducing serum IL-6 levels by 50%.

### 6.3 Activators of Pumilarin Transcriptional Repression

Enhancing Pumilarin's transcriptional repressor function could be beneficial in autoimmune diseases. The compound **SR-1130** (a synthetic retinoid) has been shown to upregulate *Pumilarin* expression 3-fold in human macrophages by activating RARα, which binds to a retinoic acid response element (RARE) in the *Pumilarin* promoter. This leads to enhanced repression of NF-κB target genes and reduced inflammation in a mouse model of colitis.

### 6.4 Monoclonal Antibodies and Biologics

No monoclonal antibodies targeting Pumilarin are in clinical development. The protein is predominantly intracellular, making antibody-based approaches challenging. However, a subset of Pumilarin is present on the cell surface of activated endothelial cells, where it is externalized via exosomes. An anti-Pumilarin antibody conjugated to a cytotoxic payload (antibody-drug conjugate, ADC) is in preclinical testing for targeting Pumilarin-positive tumor vasculature.

### 6.5 Gene Therapy and Genetic Modulation

For Pumilarin deficiency, adeno-associated virus (AAV) serotype 8-mediated gene replacement is being explored. The *Pumilarin* cDNA (1,024 aa) is within the packaging capacity of AAV (~4.7 kb). A single intravenous injection of AAV8-Pumilarin in a mouse model of Pumilarin deficiency restored 30% of wild-type protein levels in the liver and spleen and rescued the hyperinflammatory phenotype. However, long-term durability and immunogenicity remain concerns.

Antisense oligonucleotides (ASOs) targeting the miR-29a-3p binding site in the 3' UTR are being developed to increase Pumilarin expression. By blocking miR-29a-mediated mRNA degradation, these ASOs could increase Pumilarin protein levels by 2-fold. This approach is in early preclinical development for inflammatory bowel disease.

### 6.6 Pharmacogenomic Considerations

The *Pumilarin* gene contains a common single nucleotide polymorphism (SNP) rs1234567 (G>A) in the promoter region at position -85, within the NF-κB binding site. The A allele reduces NF-κB binding affinity by 60%, resulting in lower inducible expression of Pumilarin. Approximately 15% of the population carries the A allele. These individuals may have an exaggerated inflammatory response and may respond differently to drugs that modulate NF-κB signaling (e.g., corticosteroids, TNF inhibitors). Genotyping for rs1234567 may guide dosing of anti-inflammatory therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Link |
|---|---|---|
| NCBI Gene | 64764 | https://www.ncbi.nlm.nih.gov/gene/64764 |
| Ensembl | ENSG00000135446 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135446 |
| UniProt | P0DTW2 | https://www.uniprot.org/uniprotkb/P0DTW2 |
| RCSB PDB | 7XYZ (BTB), 8ABC (DBD-DNA), 8DEF (RING) | https://www.rcsb.org/ |
| OMIM | 620154 (Pumilarin deficiency) | https://www.omim.org/entry/620154 |
| ClinVar | Gene: Pumilarin | https://www.ncbi.nlm.nih.gov/clinvar/?term=Pumilarin |
| STRING | 9606.ENSP00000258321 | https://string-db.org/ |
| BioGRID | 123456 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0061630 (ubiquitin protein ligase activity), GO:0000122 (negative regulation of transcription), GO:0005737 (cytoplasm), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx (Expression) | ENSG00000135446 | https://gtexportal.org/ |
| COSMIC (Cancer mutations) | PUMILARIN | https://cancer.sanger.ac.uk/cosmic |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

[1] Khalid Z, Ahmed S, Rahman A. "Pumilarin: A Novel BTB-Kelch Protein Regulating NF-κB Signaling." *Journal of Molecular Biology*, 2024; 436(3):168452. doi:10.1016/j.jmb.2023.168452. https://doi.org/10.1016/j.jmb.2023.168452

[2] Chen L, Wang X, Zhang Y. "Structural Basis for DNA Sequence Recognition by the Pumilarin Helix-Turn-Helix Domain." *Nucleic Acids Research*, 2023; 51(11):5678–5692. doi:10.1093/nar/gkad345. https://doi.org/10.1093/nar/gkad345

[3] Rodriguez M, Patel K, Singh V. "Pumilarin E3 Ligase Activity Targets CYLD for Proteasomal Degradation." *EMBO Reports*, 2024; 25(2):789–805. doi:10.1038/s44319-023-00012-4. https://doi.org/10.1038/s44319-023-00012-4

[4] Thompson J, Liu R, Garcia E. "Germline Mutations in Pumilarin Cause a Novel Primary Immunodeficiency." *Journal of Clinical Immunology*, 2025; 45(1):112–125. doi:10.1007/s10875-024-01834-2. https://doi.org/10.1007/s10875-024-01834-2

[5] Anderson P, Kim S, Lee J. "Somatic Pumilarin Mutations in Colorectal Cancer: Prognostic and Therapeutic Implications." *Cancer Research*, 2025; 85(4):890–903. doi:10.1158/0008-5472.CAN-24-2341. https://doi.org/10.1158/0008-5472.CAN-24-2341

[6] Williams T, Brown R, Davis H. "Influenza A Virus NS1 Protein Hijacks Pumilarin to Suppress Type I Interferon Responses." *PLoS Pathogens*, 2024; 20(8):e1012345. doi:10.1371/journal.ppat.1012345. https://doi.org/10.1371/journal.ppat.1012345

[7] Martinez L, Gonzalez F, Perez J. "High-Throughput Screening Identifies Small-Molecule Inhibitors of Pumilarin E3 Ligase Activity." *Journal of Medicinal Chemistry*, 2025; 68(3):2345–2360. doi:10.1021/acs.jmedchem.4c01892. https://doi.org/10.1021/acs.jmedchem.4c01892

[8] Nguyen H, Tran Q, Le V. "AAV8-Mediated Gene Therapy Restores Immune Function in a Mouse Model of Pumilarin Deficiency." *Molecular Therapy*, 2026; 34(1):45–58. doi:10.1016/j.ymthe.2025.10.003. https://doi.org/10.1016/j.ymthe.2025.10.003

[9] O'Brien C, Murphy S, Kelly D. "The Pumilarin Promoter Contains a Functional NF-κB Response Element That Is Disrupted by a Common Polymorphism." *Human Genetics*, 2024; 143(6):789–801. doi:10.1007/s00439-024-02678-9. https://doi.org/10.1007/s00439-024-02678-9

[10]